Do patients with the heparin-induced thrombocytopenia syndrome have heparin-specific antibodies?  by Adams, John G. et al.
Do patients with the heparin-induced 
thrombocytopenia syndrome have 
heparin-specific antibodies? 
John G. Adams, Jr., MD, Loren J. Humphrey, MD, PhD, Xinchao Zhang, MD~ 
and Donald Silver, MD, Columbia, Mo. 
Purpose: Patients with the heparin-induced thrombocytopenia syndrome (HIT) have 
heparin-associated antibodies (HAb +), which, in the presence of heparin, are responsible 
for platelet activation and aggregation. This study addressed the questions: (1) are the 
antibodies specific for heparin; and (2) how do the antibodies cause platelet aggregation? 
Methods: Plasmas from 79 patients with HIT were divided into seven plasma samples: 
HAb+ plasma sample 1 (24 pooled plasmas); HAb+ plasma sample 2 (50 pooled 
plasmas); and HAb + plasma samples 3 through 7 (individual plasmas). Normal patient 
plasmas were used as controls (HAb-).  
Results: All seven HAb + plasma samples caused platelet aggregation (PLA) in the presence 
of heparin and formed a precipitation line with heparin in gel immunodiffusion plates 
(HAb- plasmas did neither). The HAb + plasma samples reacted with heparin, as 
determined by immunoprecipitation ha sodium dodecylsulfate-polyacrylamide gel, with 
the production of a band at 50 kd (no band with HAb-  plasmas). The plasma samples 
1 and 2 were passed over heparin sepharose beads three times; the unabsorbed plasmas 
produced 3 + PLA, the first effluent produced 2 + PLA, and the second and third effluents 
produced no PLA. The heparin sepharose beads stained 3 +, 2 +, and 1 +, after the 
respective passages, with fluorescein-labeled goat sera containing anti-human immuno- 
globulin G antibody. HAb + plasma samples were digested with pepsin to separate the 
F(ab')2 fragments from the Fc fragments. The F(ab')2 fragments reacted with heparin as 
determined by immunoprecipitation n sodium dodecylsulfate-polyacrylamide gel with 
the production of a band at 25 kd, but did not cause PLA in the presence of heparin. 
Conclusion: Patients with HIT have heparin-specific antibodies that react with heparin in 
a classic F(ab')z reaction and require the Fc fragment for platelet aggregation. (J VASc 
SURG 1995;21:247-54.) 
Heparin-induced thrombocytopenia is an idio- 
syncratic reaction that occurs in patients receiving 
heparin. The thrombocytopenia h s two distinct 
patterns ofpl"esentation. The most common type, the 
acute type, occurs within 2 to 3 days of the onset of 
heparin therapy; the thrombocytopenia is transient, 
and its sequelae are not clinically significant. The de- 
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layed type occurs in 0.6% to 31% of patients 
receiving heparin, is associated with thrombohem- 
orrhagic complications, and is known as the 
heparin-induced thrombocympenia syndrome 
(HIT). When recognized and treated late, the mor- 
bidity and mortality rate of HIT has been 60% and 
25%, respectively. 1,2With prompt recognition and 
early treatment of HIT, the morbidity and mortality 
rates can be reduced to 25% and 12%, respec- 
tively, m 
The pathophysiologic condition of HIT  has not 
been well defined. It has been suggested that HIT is 
mediated by an immunoglobulin G (IgG)-heparin 
immune complex, involving both F(ab')2 and Fc 
portions of the IgG molecule, which activates 
platelets?  It has been shown that the IgG-heparin 
immune complex interacts with the Fc receptor on 
the surface of platelets. 9 This interaction, in turn, 
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activates platelets by stimulating a wide variety of 
signalling pathways. 
This study was designed to address two 
questions: (1) are the antibodies responsible for HIT 
specific for heparin; and (2) what is the mechanism 
by which these antibodies cause platelet aggregation? 
METHODS 
Heparin antibody test. HIT should be sus- 
pected when a patient receiving heparin has devel- 
opment of a falling or persistently low platelet count, 
a resistance to anticoagulation with heparin, and/or 
new thromboembolic (rarely hemorrhagic) events. 
After discontinuation f heparin exposure, the diag- 
nosis is confirmed by cessation of the thromboem- 
bolic events, areturn of the platelet count to normal 
within 1 to 3 days and, in most instances, by platelet 
aggregometry. Our method of testing for the heparin 
antibody with platelet aggregometry has been previ- 
ously described) °'ll Briefly, samples of the patient's 
plasma re tested for their ability to aggregate normal 
donor platelets in the presence of heparin (porcine; 
Elkins-Sinn, Inc., Cherry Hill, N.I.). All aggregation 
was performed in duplicate in a Chrono-Log dual 
channel aggregometer (Chrono-Log, Havertown, 
Pa.). The results are graded as no platelct aggregation 
(0) to strong platelet aggregation (3+ ))1 
Immtmodiffusion. Immunodiffusion testing 
was performed with immunodiffusion plates with 
1% agarose in phosphate buffered saline solution 
(PBS) (pH 7.4). Tile central wells were loaded 
with 10 ~xl of hcparin (1000 U/ml). Plasmas from 
patients with heparin-induced antiplatelet anti- 
bodies (I-LAb + ) and plasmas from control patients 
(HAb- )  were placed in the peripheral wells. The 
plates were incubated in a humidity chamber for 24 
hours at room temperature and then were evaluated 
for the presence or absence of precipitant lines. 
Immunoprecipitation. HAb + and HAb-  
plasmas were centrifuged at1900g for 15 minutes to 
remove the lipid. PBS was added (1:1, volume: 
volume [v:v]), and 3.0 ml were passed over a pro- 
tein A column. The column was washed with 50 
ml of PBS. The IgG was eluted by passing 500 ~xl of 
0.2 mol/L glycine buffer (pH 2.0) over the protein A 
column to obtain IgG + and IgG - effluents, respec- 
tively. The effluents were neutralized with 1 mol/L 
tris-hydrochloric a id (1:10, V:V; pH 9.0). IgG+ 
and IgG-  effluents were incubated with sepharose 
beads (CL-6B; Pharmacia, Piscataway, N.J.) at room 
temperature for 30 minutes to absorb out substances 
that cause nonspecific reactions with sepharose. Next, 
10 ~1 of IgG + and IgG-  effluents (5 ~g IgG/pA) 
were incubated with 50 ~tl ofheparin-sepharose beads 
(CL-6B) for 12 hours at 4 ° C. The heparin-sepharose 
beads were washed five times with PBS, and the 
pellets were saved. To each pellet, 50 ~xl of sodium 
dodecylsulfate (SDS) reducing buffer was added, and 
the mixture was heated to 95 ° C for 4 minutes. After 
centrifugation, each supernatant was removed and 
loaded on SDS-polyacrylamide gel(SDS-PAGE) for 
electrophoresis. 12 The gel was then stained with 
Coomassie blue (Sigma Chemical Co., St. Louis, 
Mo.). Protein bands of different molecular weights 
were identified by comparison with known standard 
protein bands. 
Qualitative absorption test. HAb+ plasmas 
(1.5 ml) were passed for 30 minutes through an 800 
~1 heparin-sepharose column. The effluent (1.5 ml 
plasma + 1.0 ml PBS) was collected and concen- 
trated via a concentrator (30 kd; Amicon Inc., 
Beverly, Mass.) to 1.5 ml. A portion of the effluent 
(0.5 ml) was saved as effluent-l, and the heparin- 
sepharose beads were saved as pellet-1. The remain- 
ing 1.0 ml of effluent was passed for 20 minutes 
through asecond 800 txl heparin-sepharose column. 
The effluent (1.0 ml plasma + 1.0 ml PBS) was 
collected and concentrated to 1.0 ml with a concen- 
trator. A portion of the effluent (0.5 ml) was saved as 
effluent-2, and the heparin-sepharose beads were 
saved as pellet-2. The remaining effluent (0.5 ml) was 
passed for 10 minutes through a third 800 Ixl 
heparin-sepharose column. The effluent (0.5 ml 
plasma + 1.0 ml PBS) was collected and concen- 
trated to 0.5 ml with a concentrator. This effluent was 
saved as effluent-3, and the heparin-sepharose beads 
were saved as pellet-3. HAb+ plasmas passed 
through three sepharose columns, instead ofheparin- 
sepharose columns, provided control effluents and 
pellets. 
The three test effluents (0.3 ml each) and the three 
control effluents (0.3 ml each), as noted above, were 
mixed with 0.2 ml platelet-rich plasma, 50 ~1 heparin 
(final concentration f 1 tmit/ml) and evaluated with 
duplicate platelet aggregometry; unabsorbed HAb + 
plasmas were used as controls. Immunofluorescent 
testing was performed on test and control pellets. 
One hundred microliters of pellets 1 through 3 were 
washed three times with PBS. The pellets were then 
incubated with 20 Ixl of 1 : 10 fluoresccin isothiocy- 
anate-labeled (FITC) goat sera containing anti- 
human IgG antibody for 1 hour at room tempera- 
mrc. The pellets were again washed with PBS three 
times, and pellet smears were placed on slides. The 
smears were examined with fluorescent microscopy 
for the presence of fluorescence. Heparin-sepharose 
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beads (CL-6B), which were not exposed to plasma, 
served as control pellets. 
Isolation of F(ab')2 fragments. Eight miUi- 
grains of IgG + obtained by protein A column from 
t-LAb + plasma was added to 2 ml of 100 mmol/L 
sodium citrate (pH 3.5) and incubated with 40 txg 
pepsin (Sigma Chemical Co.) for 16 hours at 
37 ° C. Next, 300 txl of 3 mol/L tris buffer (pH 
8.8) was added. Intact IgG and the Fc fragments 
were separated from the F(ab')2 fragments by 
passing the solution through a protein A column 
as previously described. The effluent was dialyzed 
against PBS for 12 hours. The yield and purity of 
the F(ab')2 fragments were determined by immu- 
nodiffusion with anti-human IgG F(ab')2 (Sigma 
Chemical Co.) antibodies. The effluent containing 
the F(ab')2 fragments was concentrated to 2 mg/ml 
with the Amicon concentrator (Amicon, Inc., Bev- 
erly, Mass.) and then subjected to platelet aggre- 
gomet U and immunoprecipitation with heparin- 
sepharose in SDS-PAGE as described above. 
RESULTS 
Heparin antibody detection. Plasmas from 79 
patients were identified by platelet aggregometry as 
having the heparin antiplatelet antibody by the 
demonstration f strong (3 + ) platelet aggregation. 
These plasmas, obtained between January 1989 and 
January 1991, were divided into seven test samples: 
HAb+ plasma sample 1 (24 pooled plasmas); 
HAb + plasma sample 2 (50 pooled plasmas); and 
HAb+ plasma samples 3 through 7 (individual 
plasmas). 
Immunodiffusion. Immunodiffusion assays 
were performed in duplicate on each of HAb+ 
plasma samples 1 through 7 with concurrent assays 
on HAb-  plasma controls. Each of the HAb+ 
plasma samples i through 7produced a precipitation 
line after 24 hours incubation with heparin in the 
immunodiffusion plates, whereas none of the HAb - 
plasma controls produced a precipitation line. 
Immunoprecipitation. Immunoprecipitation 
tests were performed in duplicate with IgG + efflu- 
ents 1 through 7. IgG-  effluents were used as 
controls. Each supernatant obtained from incubation 
of IgG+ effluents 1 through 7 with heparin- 
sepharose beads produced a 50 kd band when loaded 
on SDS-PAGE (Fig. 1). The IgG-  supernatants did 
not produce a band at 50 kd. 
Qualitative absorption. Before qualitative ab- 
sorption testing, HAb + plasma samples 1 and 2 
produced 3 + platelet aggregation on exposure to 
heparin and platelet-rich plasma. Qualitative absorp- 
65 kd 
45 kd 
.31 
Fig. 1. Demonstration f 50kd bands produced in SDS- 
PAGE by IgG + plasmas 1 through 7 after immunopre- 
cipitation after heparin exposure. IgG + 6 did not stain as 
heavily as other plasmas, but 50 kd band can be identified. 
Identity of bands was confirmed by fluorescentqabeled 
anti-IgG reagents. (ST/) represents purified standard pro-. 
reins (14.4 kd to 97.4 kd), BIO-RAD; 1-7 represent IgG + 
plasmas 1 through 7). 
tion tests were performed in duplicate on HAb + 
plasma samples 1 and 2. HAb + plasma samples 1 
and 2 were passed through asepharose column instead 
of a heparin-sepharose column to produce the control 
effluents. All three control effluents produced 3 + 
platelet aggregation on exposure to heparin and 
platelet-rich plasma. 
HAb+ plasma samples 1 and 2 were passed 
through a heparin-sepharose column to produce the 
test effluents. The test effluents howed the following 
results on exposure to heparin and platelet-rich 
plasma: effluent-1 produced 2+ platelet aggrega- 
tion; effluent-2 produced no platelet aggregation; 
and effluent-3 produced no platelet aggregation 
(Table I). 
Pellets 1 through 3 of the control HAb + plasma 
samples 1 and 2 (passed through a sepharose column 
instead of a heparin-sepharose column) showed no 
staining on exposure to FITC-labeled goat sera 
containing anti-human IgG antibody (Table II). 
Pellets i through 3of the test HAb + plasma samples 
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Table I. Heparin-induced platelet aggregation after absorption of plasma with heparin-sepharose 
beads (CL-6B) 
Effluent- 1 Effluent-2 Efiguent-3 
Plasma sample 1(HAb + ), control 3 + 3 + 3 + 
Plasma sample 2 (HAb + ), control 3 + 3 + 3 + 
Plasma sample 1(HAb + ), test 2 + 0 0 
Plasma sample 2 (HAb + ), test 2 + 0 0 
Effluents 1 through 3 from control HAb + plasma samples 1 and 2 uniformly demonstrated 3 + platelet aggregation on exposure to 
heparin- and platelet-rich plasma in the aggregometer. Effluents I through 3 from HAb + plasma samples 1 and 2 demonstrated decreased 
platelet aggregation on exposure to heparin- and platelet-rich plasma in the aggregometer after absorption with heparin-sepharose b ads 
(CL-6B). Blatelet aggregation was graded from none (0) to strong (3 + ). 
Table II. Immunofluorescence of heparin-sepharose pellets (CL-6B) to anti-human IgG after 
progressive absorption 
Pellet-1 Pellet-2 Pellet-3 
Plasma sample 1 (HAb + ), control 
Plasma sample 2 (HAb + ), control 
Plasma sample 1 (HAb + ), test 
Plasma sample 2 (HAb+), test 
Control pellets 
0 0 0 
0 0 0 
3+ 2+ 1+ 
3+ 2+ 1+ 
0 
Heparin-sepharose pellets I through 3 from control HAb + plasma samples 1 and 2 did not stain on exposure to fluoroscein-labeled goat 
sera containing anti-human IgG antibody. Pellets 1 through 3 from test HAb + plasma samples 1 and 2 demonstrated progressively 
decreasing fluorescence on exposure to the anti-human IgG antibody. Control pellets did not stain on exposure to the anti-human IgG 
antibody. Irmnunofluorescence was graded from none (0) to strong (3 + ). 
i and 2 (passed through aheparin-sepharose column) 
stained 3+, 2 +, and 1 +, respectively, on exposure 
to FITC-labeled goat sera containing anti-human 
IgG antibody. Control pellets (heparin-sepharose 
beads (CL-6B) not exposed to plasma) showed no 
staining on exposure to FITC-labeled goat sera 
containing anti-human IgG antibody. 
F(ab')2 fragment immunoprecipitation a d 
platelet aggregometry. The isolated F(ab')2 frag- 
ments from HAb + plasma samples 1 and 2 were 
incubated with sepharose beads followed by incuba- 
tion with heparin-sepharose beads in duplicate 
(n = 5). The pellets were washed with PBS, heated, 
and centrifuged, yielding the supernatant that was 
loaded on SDS-PAGE for electrophoresis. This 
supernatant produced a 25 kd band with electro- 
phoresis (Fig. 2). When evaluated with platelet 
aggregometry, the isolated F(ab')2 fragments from 
HAb + plasma samples 1 and 2 failed to produce 
platelet aggregation i the presence of heparin. 
DISCUSSION 
The HIT syndrome, first described 31 years ago, 4 
continues to be a significant complication of heparin 
administration. Although the clinical recognition and 
treatment have been well characterized, ~ the patho- 
physiologic ondition of the HIT syndrome remains 
incompletely understood. An immunologic basis for 
the HIT syndrome was suggested in 1973. 4 The 
immunologic basis was strengthened in 1977 when a 
factor within the IgG fraction was found to promote 
platelet aggregation i  the presence of heparin. 13 
Complement fixation studies, aggregation studies, 
agarose countercurrent immunoelectrophoretic stud- 
ies, Ouchterlony diffusion studies, and heparin- 
platelet absorption studies upported the thesis of a 
heparin-dependent platelet membrane antibody in 
some patients receiving heparin, i°'laqs Studies have 
demonstrated that the heparin-dependent platelet- 
activating factor is an IgG, s,6,1621 although the factor 
has been isolated in IgM fractions in a few pa- 
tients. 13,=,23 Despite the large body of evidence 
suggesting an immunologic basis for HIT, the 
isolation of an antibody specific for heparin has been 
difficult. Several theories have been proposed to 
explain the exact mechanism by which the antibody, 
platelets, and heparin interact o produce platelet 
aggregation. However, it is generally agreed that the 
antibody and heparin are bound together on the 
platelet surface forming an immune complex. This 
complex has been shown to cause platelet activation 
and aggregation through interaction with the Fc 
receptor as described by Pfueller et al., 24 Adelman et 
al.,2s and Chong et al.26 
The specificity of the antibody that interacts with 
heparin to produce platelet aggregation and activa- 
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tion has not been clearly established. This study was 
performed to determine the specificity of the heparin- 
antibody reaction and to determine the pathway(s) 
by which the antibody causes platelet activation. The 
qualitative absorption experiments in this study 
demonstrated that the factor in the plasma of patients 
with HIT, which produces platelet aggregation on 
exposure to heparin, can be absorbed out with 
heparin-sepharose. These results suggest hat the 
antibody, IgG, reacts directly with heparin, and it is 
this antibody that causes platelet aggregation. 
In this study, the immunodiffusion assays dem- 
onstrated production of a precipitant line on expo- 
sure of I-LAb + plasma to heparin. Furthermore, in
the immunoprecipitation studies each supernatant 
obtained from incubation of IgG+ effluents 1 
through 7 with heparin-sepharose beads produced a
50 kd band when loaded on SDS-PAGE. This band 
most likely represents heparin-specific antibody in the 
IgG. These results suggest that the antibody reacts 
with heparin directly and that the antibody-heparin 
reaction can occur in the absence of platelets. In 
addition, isolated F(ab')2 fragments from patients 
with HIT produced a 25 kd band in SDS-PAGE after 
incubation with heparin-sepharose beads in immu- 
noprecipitation. When exposed to heparin and 
platdet-rich plasma in the aggregometer, the isolated 
F(ab')2 fragments did not produce platelet aggrega- 
tion. These findings suggest that the F(ab')2 region 
of the IgG specifically reacts with heparin, but the 
F(ab')2-heparin complex in the absence of the Fc 
portion of the immunoglobulin cannot produce 
platelet aggregation. 
The findings in this study are in agreement with 
other studies that have provided evidence to support 
the concept hat the heparin-antibody reaction is 
specific. IgG from patients with the HIT syndrome 
was incubated with tritiated heparin in a sucrose- 
density gradient o evaluate the concept of specific- 
ity. 27 The position of tritiated heparin before and 
after incubation with the IgG was determined by the 
presence of radioactivity on the gradient. With the 
addition oflgG to the sucrose density gradient, a shift 
in the position oftritiated heparin occurred, resulting 
in the presence of radioactive heparin within the IgG 
range after the reaction. These results strongly 
suggested an antibody-heparin eaction. 
Kelton et .9.1. 6recently have shown that the platelet 
release reaction that occurs in the presence ofheparin 
and IgG from patients with HIT can be inhibited by 
purified F(ab')2 from patients with HIT but not 
purified F(ab')2 from control patients. This same 
group has also demonstrated inhibition of the platelet 
65 kd 
45 kd 
25 kd 
i 2 3 4 
Fig. 2. Example of 25 kd band (black a,~row represents 
F(ab')2 fragments) produced in SDS-PAGE after immu- 
noprecipitation after heparin exposure of isolated F(ab')2 
fragments ofHAb + plasma sample 1. Identity of the bands 
was confirmed by fluorescent-labeled anti-IgG reagents. (J 
represents purified standard proteins (14,4 kd to 66.2 kd), 
BIO-RAD; 2 represents isolated F(ab')2 fragment of 
HAb+ plasma sample 1; 3 represents HAb- plasma; 4 
represents IgG+ plasma 1). 
release reaction with purified animal orhuman Fc and 
a monoclonal ntibody against the Fc receptor. These 
observations indicate that the heparin-antibody reac- 
tion is specific and initiates platelet aggregation and 
activation by binding to the platelet Fc receptors. 
Other investigators contend that the antibody- 
heparin reaction is not specific and that platelet 
factor(s) must be present for the antibody-heparin 
complex to form. In this setting, heparin binds to 
platelet membrane protein(s) initially; the unique 
microenvironment of he platelet surface then poten- 
tiates the binding of the IgG to the heparin-platelet 
complex. After the binding of the IgG to the 
heparin-platelet complex, platelet aggregation and 
activation are initiated through the platelet Fc 
receptor. This model is attractive because direct 
heparin antibody reactions have been difficult to 
demonstrate. ~4,2s,27 It has also been proposed that 
this model accounts for the inhibition of platelet 
activation in vitro with use of supratherapeutic 
heparin concentrations because the antigen (heparin) 
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excess causes impaired formation of the immune 
complex. 28 Although this is certainly an attractive 
model, the findings of this study demonstrate hat 
there is direct binding of antibody to heparin in the 
absence of platelets. The finding that supratherapeu- 
tic concentrations of heparin inhibit platelet activa- 
tion is also consistent with a specific antibody- 
heparin interaction. High concentrations of heparin 
may lead to displacement of heparin-antibody com- 
plexes from the platelet membrane. This explanation 
is supported by previous studies in which heparin 
inhibition experiments, human and animal Fc inhi- 
bition experiments, monoclonal anti-Fc receptor 
inhibition experiments, and inhibition by F(ab')2 
fragments indicated that the mechanism of platelet 
activation was the binding of the heparin-antibody 
complex to the platelet Fc receptor. 6 
Greinacher et al. 29,30 have suggested that the 
anti-heparin antibody in the sera of patients with 
HIT reacts with the polysulfated region of the 
heparin molecule in a nonspecific manner. This 
group has demonstrated that, like heparin, dextran 
sulfate and pentosan polysulfate (polysulfated oli- 
gosaccharides, which are heparinlike substances) can 
cause platelet activation on exposure to either the 
serum or its IgG fraction from patients with HIT. In 
contrast o standard heparin, de-N-sulfated heparin 
(standard heparin with desulfation of the amino- 
bound sulfate group) did not cause platelet activation 
when exposed to the sera of patients with HIT. The 
investigators concluded that the heparin-antibody 
reaction was not specific and that the degree of 
sulfation of the oligosaccharide appeared to be the 
most important determinant ofantibody binding and 
subsequent platclet activation. Although these find- 
ings deserve consideration, one must remember that 
heparin is a natural substance and immunologic 
cross-reactivity ofheparin-associated antibodies with 
endogenous cell surface-associated glycosaminogly- 
cans seems plausible. 
Recently, evidence has been presented to suggest 
that platelet factor 4 (PF4) plays an integral role in 
the binding of the antibody and heparin. 31 These 
findings indicate that the antibody binds to heparin 
complexed with PF4 in solution or with glycosami- 
noglycan molecules on the surface of endothelial cells 
to form an immune complex that then binds to the 
platelet Fc receptor and leads to aggregation and 
activation. This theory explains many aspects of the 
immunologic basis of HIT that have not been 
adequately explained by other models, although 
further studies are required to test its validity. 
The pathophysiology of the HIT syndrome 
remains controversial. This study was designed to 
determine the specificity of the heparin-antibody 
reaction and to determine the pathway(s) by which 
the antibody causes platelet activation. The results of 
the immunodiffusion, immunoprecipitation, platelet 
aggregation, and immunofluorescence experiments 
with HAb+ plasmas indicate that one of the 
mechanisms ofproduction of the HIT syndrome is a 
reaction between a heparin-specific IgG antibody and 
heparin, which can occur in the absence of platelets. 
The clinical significance of the demonstration that the 
reaction can occur in the absence of platelets is that 
therapy aimed solely at blocking platelet aggregation 
(e.g., aspirin) does not treat the underlying patho- 
physiologic ondition. The results of the immuno- 
precipitation and platelet aggregation experiments 
with the isolated F(ab')2 fragments indicate that (1) 
the F(ab')2 region of the IgG specifically reacts with 
heparin in a classical F(ab')2 reaction; and (2) in the 
absence of the Fc portion of the immunoglobulin, the 
F(ab')2-heparin complex does not produce platelet 
aggregation. These findings are in agreement with 
other studies that have provided evidence to support 
the concept hat the heparin-antibody reaction is 
specific and that the Fc portion of the immunoglob- 
ulin is required for platelet activation and aggre- 
gation. 
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DISCUSSION 
Dr. Thomas W. Wakefield (Ann Arbor, Mich.). Dr. 
Adams et al. have attempted to elucidate the mechanism of 
HIT. They have concluded that patients with HIT have 
heparin-specific antibodies and that these antibodies react 
in a classic F(ab')2 reaction pattern requiring the platelet Fc 
receptor for platelet aggregation to occur. This study adds 
to our knowledge about he mechanism ofheparin-induced 
platelet aggregation. 
Others have found both similar and different findings. 
For example, Adelman et al. 2s reported that heparin- 
associated thrombocytopenia is initiated by an interaction 
between the patient's IgG antibody, heparin, and the 
platelet surface, that this platelet aggregation is mediated by 
the platelet Fc receptor, that access to this receptor is 
blocked by intact antibodies that bind to von WiUebrand 
factor binding sites on the glycoprotein Ib receptor, 
suggesting that the glycoprotein Ib receptor and the 
platelet Fc receptor are closely associated but not the 
same, and importantly platelet aggregation requires ac- 
tivation of platelet fibrinogen receptors on the platelet 
receptor glycoprotein IIb/IIIa. In 1992, Greinacher et 
al. 29 demonstrated that heparin-associated thrombocyto- 
penia was caused not only by heparin but also by 
unfractionated heparin and preparations of polysulfated 
oligosaccharides, such as dextran sulfate. These authors 
felt that the main contributing mechanism to heparin- 
associated thrombocytopenia w s the degree of sulfona- 
tion of the polysulfated oligosaccharide, not the structure 
of its sugar backbone or its antithrombin-I!I binding 
efficiency. 
From your studies, do you know the location of the 
platelet Fc receptor? 
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Why do you disagree with others who suggest that the 
antibody in this condition is not heparin-specific? Mthough 
the plasma factor producing platelet aggregation was 
absorbed out with heparin sepharose, does this prove that 
the antibody is heparin specifc? 
Do you have any thoughts concerning the degree of 
sulfonation of heparin and this effect on the HIT? 
Dr. John G. Adams, Jr. With regard to the first 
question about he location of the Fc receptor, I have to say 
that we do not know the exact location of that receptor. 
Why do we disagree with others who think that this is 
a nonspecific reaction and why do we argue that it is a 
specific reaction? I think our data and the data presented by 
others with regard to immunodiffusion testing, immuno- 
precipitation, platelet aggregation, and electrophoretic 
diffusion experiments provide substantial evidence, albeit 
some of it indirect, that this is a specific reaction. 
Kelton et al. 6 have shown that the F(ab')2 fragments 
from the sera of patients with H IT  can be used to block 
platelet aggregation in the presence of heparin, whereas 
F(ab')2 fragments from control sera does not block that 
reaction. 
On the clinical level, I think that if this were a 
nonspecific reaction, we would see a higher incidence of the 
H IT  syndrome. 
Even though we were able to absorb out with heparin 
the factor-producing platelet aggregation, this does not 
prove that the antibody is specific for heparin. We can 
strengthen our argument by repeating these experiments, 
specifically the immunoprecipitation part of our experi- 
ments, using different heparinlike substances. The studies 
are planned. 
Last, the relationship of the degree of sulfation of the 
heparin molecule and the H IT  syndrome is certainly 
interesting. Greinacher et al. 29'3° have shown that, with 
increasing sulfation of heparin and heparinlike molecules, 
the degree of cross-reactivity resulting in platelet aggrega- 
tion increases. These findings deserve consideration, but we 
must remember that heparin is a natural substance, and a 
certain amount of immunologic ross-reactivity is to be 
expected with the glycosaminoglycans of the endothelial 
cell. 
Dr. Michael Sobel (Richmond, Va.). I 'm always 
grateful to see serious scientific investigations of an 
important clinical problem like this. But at the same time, 
I'd be disappointed if people believed that these antibodies 
were mainly directed against heparin, because I 'm not 
convinced that you've shown that in this study. For 
example, it would have been important to show that these 
antibodies performed precipitation arcs with heparin, but 
not with heparinlike polysaccharides. That would have 
suggested more specificity. 
There have also been some very exciting recent studies 
suggesting that the primary antigen for these antibodies i  
a mixture of platelet factor IV and heparin, and those 
reports have been very convincing and impressive. I wish I 
had thought of the idea myself. But some of your data 
actually supports that contention. For example, the heparin 
sepharose columns that you used to filter these plasmas 
would also have filtered out platelet factor IV, which may 
be the critical cofactor in all of these. 
Dr. Adams. I certainly agree with you that the work of 
Visentin et al. 31 with platelet factor IV is very interesting. 
We are currently repeating some of the experiments 
performed in this study, and are adding platelet factor IV. 
We also plan to test the "antibody" against other heparin- 
like molecules. 
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